← Back to Search

Endoscopic ultrasound catheter (UM-2R/3R, Olympus) for Ulcerative Colitis (EUSIBD Trial)

N/A
Waitlist Available
Led By Vu Q Nguyen, M.D.
Research Sponsored by Carilion Clinic
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Adults patients ≥ 18 years of age with CD with at least colonic involvement, UC, or non-IBD controls who have been referred for colonoscopy for clinical reasons. The clinical reasons may include colorectal cancer screening, surveillance, diagnostic for CD or UC flare, or gastrointestinal symptoms.
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 1
Awards & highlights

EUSIBD Trial Summary

This study is evaluating whether a new imaging technique can help differentiate between Crohn's disease and ulcerative colitis.

Eligible Conditions
  • Ulcerative Colitis
  • Crohn's Disease

EUSIBD Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

EUSIBD Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 1
This trial's timeline: 3 weeks for screening, Varies for treatment, and day 1 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Active Crohn's disease has significantly thicker submucosa layer compared to patients with active ulcerative colitis and non-inflammatory bowel disease controls.
Secondary outcome measures
The thickness of the mucosa layer in ulcerative colitis patients correlates to the degree of disease activity as measured by the Mayo score index.
The thickness of the submucosa layer in Crohn's disease patients correlates to the degree of disease activity as measured by the Harvey-Bradshaw clinical index and Simple Endoscopic Score index.

EUSIBD Trial Design

3Treatment groups
Experimental Treatment
Group I: Ulcerative ColitisExperimental Treatment1 Intervention
20 patients with ulcerative colitis will undergo endoscopic ultrasound assessment of the thickness of wall layers (mucosa, submucosa, muscularis propria, total wall) at the rectum and cecum region during their standard-of-care colonoscopy.
Group II: Non-IBD ControlsExperimental Treatment1 Intervention
20 patients without inflammatory bowel disease (controls) will undergo endoscopic ultrasound assessment of the thickness of wall layers (mucosa, submucosa, muscularis propria, total wall) at the rectum and cecum region during their standard-of-care colonoscopy.
Group III: Crohn's DiseaseExperimental Treatment1 Intervention
20 patients with Crohn's disease with at least colonic involvement will undergo endoscopic ultrasound assessment of the thickness of wall layers (mucosa, submucosa, muscularis propria, total wall) at the rectum and cecum region during their standard-of-care colonoscopy.

Find a Location

Who is running the clinical trial?

Carilion ClinicLead Sponsor
70 Previous Clinical Trials
12,655 Total Patients Enrolled
Vu Q Nguyen, M.D.Principal InvestigatorAssistant Professor of Medicine

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Endoscopic Ultrasound Determines Disease Activity in Crohn's Disease And Ulcerative Colitis
Vu Nguyen 2019. "Endoscopic Ultrasound Determines Disease Activity in Crohn's Disease And Ulcerative Colitis". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03863886.
All > Crohns Disease > Colitis
~10 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top